Seerlinq
Trnava
About Seerlinq
Seerlinq specializes in the development of AI-based solutions for non-invasive diagnostics, disease monitoring, and treatment optimization. The company focuses on leveraging photoplethysmography (PPG), an optical measurement technique that detects changes in the peripheral vascular bed, to advance healthcare. By analyzing vast amounts of data, including patients' medical records and genetic information, Seerlinq's AI algorithms aim to identify patterns and predict outcomes for better disease management. This approach is particularly focused on improving the quality of life for patients with heart failure, by offering more precise and personalized treatment options. Seerlinq operates in the biotechnology industry and is committed to reinventing PPG analysis to elevate non-invasive medical practices.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $982.2K
- Funding stage: Seed
- Last round: Seed (Jul 2023)
- Website: seerlinq.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/seerlinq-161118 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.